206 related articles for article (PubMed ID: 38234917)
1. The biology and treatment of Epstein-Barr virus-positive diffuse large B cell lymphoma, NOS.
Li JW; Deng C; Zhou XY; Deng R
Heliyon; 2024 Jan; 10(1):e23921. PubMed ID: 38234917
[TBL] [Abstract][Full Text] [Related]
2. Impact of treatment variability and clinicopathological characteristics on survival in patients with Epstein-Barr-Virus positive diffuse large B cell lymphoma.
Witte HM; Merz H; Biersack H; Bernard V; Riecke A; Gebauer J; Lehnert H; von Bubnoff N; Feller AC; Gebauer N
Br J Haematol; 2020 Apr; 189(2):257-268. PubMed ID: 31958882
[TBL] [Abstract][Full Text] [Related]
3. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk-stratification and management.
Beltran BE; Castro D; Paredes S; Miranda RN; Castillo JJ
Am J Hematol; 2020 Apr; 95(4):435-445. PubMed ID: 32072672
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly reveals alterations of characteristic oncogenetic pathways.
Kato H; Karube K; Yamamoto K; Takizawa J; Tsuzuki S; Yatabe Y; Kanda T; Katayama M; Ozawa Y; Ishitsuka K; Okamoto M; Kinoshita T; Ohshima K; Nakamura S; Morishima Y; Seto M
Cancer Sci; 2014 May; 105(5):537-44. PubMed ID: 24581222
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.
Ok CY; Li L; Xu-Monette ZY; Visco C; Tzankov A; Manyam GC; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Chen J; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ai W; Ponzoni M; Ferreri AJ; Farnen JP; Møller MB; Bueso-Ramos CE; Miranda RN; Winter JN; Piris MA; Medeiros LJ; Young KH
Clin Cancer Res; 2014 May; 20(9):2338-49. PubMed ID: 24583797
[TBL] [Abstract][Full Text] [Related]
6. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management.
Castillo JJ; Beltran BE; Miranda RN; Young KH; Chavez JC; Sotomayor EM
Am J Hematol; 2018 Jul; 93(7):953-962. PubMed ID: 29984868
[TBL] [Abstract][Full Text] [Related]
7. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management.
Malpica L; Marques-Piubelli ML; Beltran BE; Chavez JC; Miranda RN; Castillo JJ
Am J Hematol; 2022 Jul; 97(7):951-965. PubMed ID: 35472248
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era.
Sato A; Nakamura N; Kojima M; Ohmachi K; Carreras J; Kikuti YY; Numata H; Ohgiya D; Tazume K; Amaki J; Moriuchi M; Miyamoto M; Aoyama Y; Kawai H; Ichiki A; Hara R; Kawada H; Ogawa Y; Ando K
Cancer Sci; 2014 Sep; 105(9):1170-5. PubMed ID: 24974976
[TBL] [Abstract][Full Text] [Related]
9. [Immunophenotypes and prognosis of diffuse large B-cell lymphoma: a study of 500 cases].
Luo DL; Liu YH; Zhuang HG; Li L; Xu FP; Zhang F; Luo XL; Xu J
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):235-9. PubMed ID: 21615996
[TBL] [Abstract][Full Text] [Related]
10. TET2 and LILRB1 mutations are frequent in Epstein-Barr virus-positive diffuse large B-cell lymphoma especially in elderly patients.
Cho J; Kim E; Yoon SE; Kim SJ; Kim WS
Cancer; 2023 May; 129(10):1502-1512. PubMed ID: 36812290
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of refractory retroperitoneal Epstein-Barr virus-positive diffuse large B-cell lymphoma with secondary hemophagocytic syndrome by sequential combination regimen of PD-1 blockade and chimeric antigen receptor T cells: a case report.
Yu M; Zhang Q; Xu S; Yin T; Li F
Anticancer Drugs; 2022 Jan; 33(1):e769-e775. PubMed ID: 34387604
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: a concise review and update.
Hong JY; Ko YH; Kim SJ; Kim WS
Curr Opin Oncol; 2015 Sep; 27(5):392-8. PubMed ID: 26258272
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological analysis of neoplastic PD-L1-positive EBV
Takahara T; Satou A; Ishikawa E; Kohno K; Kato S; Suzuki Y; Takahashi E; Ohashi A; Asano N; Tsuzuki T; Nakamura S
Virchows Arch; 2021 Mar; 478(3):541-552. PubMed ID: 32803453
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
Ishikawa E; Kato S; Shimada K; Tanaka T; Suzuki Y; Satou A; Kohno K; Sakakibara A; Yamamura T; Nakamura M; Miyahara R; Goto H; Nakamura S; Hirooka Y
Cancer Med; 2018 Dec; 7(12):6051-6063. PubMed ID: 30449068
[TBL] [Abstract][Full Text] [Related]
15. Diffuse large B-cell lymphoma in a South African cohort with a high HIV prevalence: an analysis by cell-of-origin, Epstein-Barr virus infection and survival.
Cassim S; Antel K; Chetty DR; Oosthuizen J; Opie J; Mohamed Z; Verburgh E
Pathology; 2020 Jun; 52(4):453-459. PubMed ID: 32305135
[TBL] [Abstract][Full Text] [Related]
16. Programmed cell death-ligand 1 (PD-L1)
Kimura S; Oshiro Y; Iwasaki H; Kadowaki M; Mihashi Y; Sakata T; Kawauchi S; Wang Z; Takamatsu Y; Takeshita M
Clin Exp Med; 2022 Aug; 22(3):411-419. PubMed ID: 34515880
[TBL] [Abstract][Full Text] [Related]
17. CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis.
Zhao CX; Yan ZX; Wen JJ; Fu D; Xu PP; Wang L; Cheng S; Hu JD; Zhao WL
Mol Cancer; 2021 Dec; 20(1):153. PubMed ID: 34852843
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus-positive diffuse large B-cell lymphoma features disrupted antigen capture/presentation and hijacked T-cell suppression.
Jiang XN; Yu BH; Yan WH; Lee J; Zhou XY; Li XQ
Oncoimmunology; 2020; 9(1):1683346. PubMed ID: 32002294
[No Abstract] [Full Text] [Related]
19. Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Hong JY; Ryu KJ; Park C; Hong M; Ko YH; Kim WS; Kim SJ
Oncotarget; 2017 Feb; 8(8):13782-13791. PubMed ID: 28099151
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
